Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
- PMID: 37442848
- DOI: 10.1007/s12032-023-02111-9
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
Abstract
As the most frequent and vulnerable malignancy among women, breast cancer universally manifests a formidable healthcare challenge. From a biological and molecular perspective, it is a heterogenous disease and is stratified based on the etiological factors driving breast carcinogenesis. Notably, genetic predispositions and epigenetic impacts often constitute the heterogeneity of this disease. Typically, breast cancer is classified intrinsically into histological subtypes in clinical landscapes. These stratifications empower physicians to tailor precise treatments among the spectrum of breast cancer therapeutics. In this pursuit, numerous prognostic algorithms are extensively characterized, drastically changing how breast cancer is portrayed. Therefore, it is a basic requisite to comprehend the multidisciplinary rationales of breast cancer to assist the evolution of novel therapeutic strategies. This review aims at highlighting the molecular and genetic grounds of cancer additionally with therapeutic and phytotherapeutic context. Substantially, it also renders researchers with an insight into the breast cancer cell lines as a model paradigm for breast cancer research interventions.
Keywords: BRCA1/2; Breast cancer; Chemotherapy; Estrogen receptor; HER2; Mammography.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.Breast Cancer Res Treat. 2018 Feb;168(1):135-145. doi: 10.1007/s10549-017-4575-z. Epub 2017 Nov 22. Breast Cancer Res Treat. 2018. PMID: 29168063
-
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.JAMA Oncol. 2016 Oct 1;2(10):1287-1294. doi: 10.1001/jamaoncol.2016.0922. JAMA Oncol. 2016. PMID: 27281556
-
Progression and treatment of HER2-positive breast cancer.Cancer Chemother Pharmacol. 2010 Mar;65(4):611-23. doi: 10.1007/s00280-009-1208-1. Epub 2009 Dec 20. Cancer Chemother Pharmacol. 2010. PMID: 20087739
-
Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.Mol Biol Rep. 2022 Jan;49(1):717-733. doi: 10.1007/s11033-021-06863-3. Epub 2021 Nov 5. Mol Biol Rep. 2022. PMID: 34739691 Review.
-
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?J Steroid Biochem Mol Biol. 2015 Sep;153:45-53. doi: 10.1016/j.jsbmb.2015.05.005. Epub 2015 May 18. J Steroid Biochem Mol Biol. 2015. PMID: 25998416 Free PMC article. Review.
Cited by
-
Clinical Correlation of Transcription Factor SOX3 in Cancer: Unveiling Its Role in Tumorigenesis.Genes (Basel). 2024 Jun 13;15(6):777. doi: 10.3390/genes15060777. Genes (Basel). 2024. PMID: 38927713 Free PMC article. Review.
-
Prognostic and clinicopathological significance of fibrinogen-to-albumin ratio (FAR) in patients with breast cancer: a meta-analysis.World J Surg Oncol. 2024 Aug 24;22(1):220. doi: 10.1186/s12957-024-03506-2. World J Surg Oncol. 2024. PMID: 39182155 Free PMC article.
-
The value of nanocarbon contrast methylene blue based on dye-based tracer technology in sentinel lymph node biopsy for breast cancer: a systematic review and meta-analysis.PeerJ. 2025 Jun 11;13:e19546. doi: 10.7717/peerj.19546. eCollection 2025. PeerJ. 2025. PMID: 40520631 Free PMC article.
-
Axillary lymph node removal in de novo metastatic breast cancer.Gland Surg. 2024 Jul 30;13(7):1214-1228. doi: 10.21037/gs-24-130. Epub 2024 Jul 24. Gland Surg. 2024. PMID: 39175710 Free PMC article.
-
Bibliometric analysis of global research trends between gut microbiota and breast cancer: from 2013 to 2023.Front Microbiol. 2024 Jul 31;15:1393422. doi: 10.3389/fmicb.2024.1393422. eCollection 2024. Front Microbiol. 2024. PMID: 39144230 Free PMC article.
References
-
- De Rose F, Meduri B, Santis MCD, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delaloge S, Cortes J, Curigliano G. Rethinking breast cancer follow-up based on individual risk and recurrence management. Cancer Treat Rev. 2022. https://doi.org/10.1016/j.ctrv.2022.102434 . - DOI - PubMed
-
- Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, Zeng H, Zhou J, Wei W. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020. Cancer Commun. 2021;41(11):1183–94. https://doi.org/10.1002/cac2.12207 . - DOI
-
- Nel J, Elkhoury K, Velot M, Bianchi A, Acherar S, Francius G, Tamayol A, Grandemange S, Arab-Tehrany E. Functionalized liposomes for targeted breast cancer drug delivery. Bioactive Mater. 2023;24:401–37. https://doi.org/10.1016/j.bioactmat.2022.12.027 . - DOI
-
- He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T, Deng Y, He N, Li S, Fu J, Li W. A review on methods for diagnosis of breast cancer cells and tissues. Cell Prolif. 2020. https://doi.org/10.1111/cpr.12822 . - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous